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Rationale: Current assessment of COPD relies extensively on the use of spirometry, an effort-
dependent maneuver. Impulse oscillometry (IOS) is a non-volitional way to measure respiratory
system mechanics, but its relationship to structural and functional measurements in large
groups of patients with COPD is not clear.
Objectives: We evaluated the ability of IOS to detect and stage COPD severity in the prospec-
tive ECLIPSE cohort of COPD patients defined spirometrically, and contrasted with smoking and
non-smoking healthy subjects. Additionally, we assessed whether IOS relates to extent of
CT-defined emphysema.
Methods: We measured lung impedance with IOS in healthy non-smokers (n Z 233), healthy
former smokers (nZ 322) or patients with COPD (nZ 2054) and related these parameters with
spirometry and areas of low attenuation in lung CT.tive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IOS, impulse
hy; FEV1, forced expired volume in 1 s; SVC, slow vital capacity; FVC, forced vital capacity; FRC,
nd R20, respiratory resistance (Rrs) at 5 Hz, 15 Hz, and 20 Hz, respectively; R5  R20, difference in
z; AX, integrated area of low-frequency reactance; CV, coefficient of variation; X5, reactance at 5 Hz;
ntage of low attenuation areas (i.e. below 950 Hounsfields Units) on chest computed tomography;
) 151 529 5886; fax: þ44 (0) 151 529 5888.
ac.uk (P.M.A. Calverley).
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1070 C. Crim et al.Measurements and main results: In healthy control subjects, IOS demonstrated good repeat-
ability over 3 months. In the COPD group, respiratory system impedance was worse compared
with controls as was frequency dependence of resistance, which related to GOLD stage.
However, 29e86% of the COPD subjects had values that fell within the 90% confidence interval
of several parameters of the healthy non-smokers. Although mean values for impedance
parameters and CT indices worsened as GOLD severity increased, actual correlations between
them were poor (r  0.16).
Conclusions: IOS can be reliably used in large cohorts of subjects to assess respiratory system
impedance. Cross-sectional data suggest that it may have limited usefulness in evaluating the
degree of pathologic disease, whereas its role in assessing disease progression in COPD
currently remains undefined.
ª 2011 Published by Elsevier Ltd.Background
Although chronic obstructive pulmonary disease (COPD) is
increasingly recognized for its associated systemic mani-
festations,1,2 the diagnosis and severity of airflow limitation
requires the spirometric measurement of pulmonary func-
tion, as indicated by the forced expired volume in 1 s
(FEV1).
3 Moreover, the current international COPD treat-
ment guidelines proffer both pharmacologic and non-
pharmacologic recommendations based principally on the
FEV1. While spirometry is considered the standard by which
airflow limitation is assessed, it is well known that patient
effort and cooperation is required for optimal validity and
reproducibility.4 Somewhat more complex tests to assess
pulmonary function include measurement of lung volumes,
airways resistance (Raw) or its reciprocal conductance (Gaw)
with body plethysmography, or assessment of gas exchange
by diffusion of carbon monoxide (e.g. DLCO). However,
assessments using plethysmography or determination of
single-breath carbon monoxide diffusion also require
patient cooperation. Therefore, there is great interest in
developing techniques that measure lung physiology inde-
pendent of patient effort.
Determination of the impedance on the respiratory
system using imposed forced oscillations at the mouth has
been described since the 1950s.5 Current technology allows
impedance and its components, resistance and reactance, to
be measured during tidal breathing with little to no coop-
eration on the part of the patient.6 Previous investigators
have characterized impedance parameters in children and
adults, with conditions such as asthma and COPD, as well as
in World Trade Center emergency workers exposed to
inhaled dust following the September 2001 terrorist
attack.7e9 However, while forced oscillation has its advan-
tages, most studies have been conducted by single investi-
gators or centers and for a technique to be useful, it is
necessary that it be reproducible and valid across centers.
The Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) trial was initiated
to identify potential parameters that may predict disease
progression in individuals with different COPD subtypes and
to identify biomarkers and/or other non-spirometric
parameters that may serve as surrogate endpoints.10 The
ECLIPSE cohort is being evaluated using quantitative
computed tomography (CT) of the lungs, providing unique
information about the degree of emphysema and airwaycompromise. In this descriptive analysis of the baseline
data, we sought to assess lung impedance parameters in
this large cohort of subjects with COPD and to compare
them with both healthy non-smoking and smoking control
subjects, across several centers on two continents. We also
hypothesized that respiratory system impedance parame-
ters could relate to the anatomical lung parenchymal
correlates, as assessed by CT. Our intention was not to use
impedance measurements as a replacement for conven-
tional spirometry in the diagnosis of COPD but to determine
whether differences exist within spirometrically defined
groups of COPD patients that could be reliably measured
and which might identify phenotypically different behav-
iors during the subsequent follow up period.Methods
The design of the ECLIPSE trial has been previously described
in detail.10 In brief, ECLIPSE is a 3-year longitudinal
prospective study designed to identify novel endpoints and
compare these with FEV1 for their ability to measure and
predict COPD severity and its progression over time. We
recruited 2164 COPD subjects aged 40e75 years inclusive
with a10 pack-year smoking history, a post-bronchodilator
FEV1 < 80% predicted and the FEV1 to forced vital capacity
(FVC) ratio 0.70. This analysis is restricted to the 2054
subjects with COPD who also had valid baseline impulse
oscillometry (IOS) measurements and the control subjects
who were either current/former smokers (10 pack-year
smoking history; n Z 322) or non-smokers (<1 pack-year;
n Z 233), aged 40e75 years with a post-bronchodilator
FEV1 > 85% and a FEV1/FVC > 0.70.Pulmonary function and IOS measurements
Spirometry and IOS were performed in the following order:
IOS, slow vital capacity (SVC), then spirometry. Pre- and
post-bronchodilator (400 mg of albuterol) IOS, SVC, FEV1,
FVC, FEV1/FVC, and FEV6 were performed at each visit with
the Jaeger MasterScope CT Impulse Oscillometry System
(Hoechberg, Germany). Spirometry was performed accord-
ing to American Thoracic Society (ATS) guidelines.3 Post-
bronchodilator FEV1 percentage predicted was determined
using the European Community Coal and Steel standards.11
Impulse oscillometry in COPD subjects 1071IOS was performed seated using a noseclip and a mouth-
piece that stabilized the tongue position and the cheeks
supported. Impulses were delivered for 20 s during tidal
breathing. A minimum of three maneuvers were performed
and all acceptable data tracings were transferred by the
investigator to a central database at Viasys Healthcare
Clinical Services (Hoechberg, Germany). The data were
initially analyzed by computer algorithms based on the
European Respiratory Society (ERS) Task Force on forced
oscillation technique testing.6 The tracings were then over-
read by trained specialists at Viasys Healthcare Clinical
Services for overall quality, and for reproducibility of the
respiratory resistance (Rrs) at 5 Hz, 20 Hz, and the integrated
area of low-frequency reactance (coefficient of variation
[CV] of selected tracings 10%, 15% and 15%, respec-
tively), as well as compliance with ERS criteria. Specified IOS
parameters for analysis included: Rrs at 5, 15 and 20 Hz (R5,
R15 and R20); reactance at 5Hz (X5) and the integrated area of
low-frequency reactance (AX) from 5 Hz to resonant
frequency (FRes). In addition, R5R20 was determined as an
index of frequency dependence of resistance.
Whole-body plethysmography was performed at selected
investigator sites, but with no attempt made to standardize
plethysmographic equipment across the sites. However,
each site submitted a complete plethysmography report to
a central reader; the report included the graphics for
functional residual capacity (FRC), Raw and SVC, as well as
numerical data from all trials, including panting frequency.
The central reader assessed each individual trial for
acceptability and each test session for repeatability based
on published recommendations.12,13 Reference values for
residual volume, FRC and total lung capacity (TLC) were
from the ATS/ERS workshop report.14Quantitative chest CT
Baseline CT scans were performed within one day of
spirometry. All scans were acquired using multi detector-
row CT scanners (GE Healthcare or Siemens Healthcare)
with a minimum of four rows and obtained in the supine
position, at suspended full inspiration without administra-
tion of intravenous contrast. Exposure settings were
120 kVp and 40 mA, and images were reconstructed using
1.0 mm (Siemens Healthcare) or 1.25 mm (GE Healthcare)
contiguous slices and a low spatial frequency reconstruc-
tion algorithm (GE Healthcare: standard, Siemens Health-
care: b35f). CT scanners were calibrated regularly using
industry and institutional standards.
All CT scans were analyzed using ‘Pulmonary Workstation
2.0’ software (VIDA Diagnostics, Iowa City, IA, USA) following
segmentation of the individual lobes.15 The extent of
emphysema (percentage of low attenuation areas [LAA%])
was estimated using the threshold technique quantifying the
percent of the total lung voxels with an apparent X-ray
attenuation value below 950 Hounsfields Units (HU).16 CT
scans were assessed to confirm that they met the study
protocol and those that did not were excluded from analysis.
CT scans that contained a significant proportion of artifact,
such as motion and excessive noise, which caused the lung
analysis software to fail during the procedure were also
excluded from study (NZ 348, 13%).Statistical analysis
Results are shown as mean  standard deviation (SD),
median values (interquartile range), frequency distribution
or percentage, as appropriate. Analyses of variance and
Cochran-Mantel-Haenszel tests, as appropriate, were used
to assess differences among the cohorts. IOS parameter
differences were determined after adjustment for age and
gender. Reproducibility of lung function measurements was
assessed through BlandeAltman plots.17 Pearson correla-
tion coefficients were calculated to evaluate the relation-
ships between lung function and other clinical assessments.
In order to calculate normal predictive equations, linear
and multiple regression were conducted. Predictors in the
regression models were age, gender, height, weight, and
body mass index (BMI).18 P values less than 0.05 were
considered significant. SAS Version 9.1 was used to carry
out all analyses. Only those subjects with at least one IOS
measurement were included in these analyses.
Results
Baseline characteristics
Table 1 summarizes the baseline demographics of the
ECLIPSE populations. Subjects with COPD were older than
both the smoking and non-smoking controls and constituted
a higher percentage of males. A greater percentage of the
smoking controls were current smokers compared with the
COPD subjects. In addition, 72% of the subjects with COPD
were receiving therapy with an ICS either alone or in
combination with a long-acting bronchodilator.
The COPD subjects had a level of airflow obstruction
that on average was moderate-to-severe; 45% were Global
Initiative for Chronic Obstructive Lung Disease (GOLD) stage
2, 42% were GOLD stage 3, and 14% were GOLD stage 4.
COPD subjects with GOLD stage 4 severity were of a similar
age and had similar tobacco exposure compared with
subjects of less severe disease; however, fewer of these
more severe subjects were current smokers.
The variability of the spirometry results between the
baseline and 3-month visit timepoints was similar for the
COPD subjects and the controls (Fig. 1). This similarity
existed despite the fact that 577/2054 (28%) subjects with
COPD had an exacerbation in the 3 month period between
baseline and Visit 2. Of these, 257 resolved within the
month prior to Visit 2. The remainder resolved more than 1
month prior to Visit 2. Three hundred forty-eight (17%) of
the COPD subjects had a change in their medications during
this 3 month period. In all 763 (37%) had either an exacer-
bation or changed medications during the period from
baseline to the 3 month visit. For most subjects with COPD,
spirometry was fairly reproducible between these two
visits. The coefficient of repeatability (i.e. the value that
95% of differences between two measurements on the same
subject would not exceed) was 0.40 L in the subjects with
COPD and it was 0.46 L for the combined group of non-
smoking and smoking control subjects.
Technically acceptable post-bronchodilator body plethys-
mographic maneuvers were obtained in a subset of control
and COPD subjects (17 non-smoking controls, 166 smoking
Table 1 Baseline demographics of ECLIPSE subjects.
NSC
(n Z 233)
CS
(n Z 322)
COPD
(n Z 2054)
GOLD 2
(n Z 915)
GOLD 3
(n Z 861)
GOLD 4
(n Z 278)
Age, years 54.3 (9.0) 55.2 (9.0) 63.4(7.1)a 63.5 (7.2) 63.7 (7.0) 62.4 (7.0)b,c
Male gender No. (%) 85 (36) 178 (55)d 1341 (65)a 550 (60) 584 (68)b 207 (74)b,c
BMI (kg/m2) 27.6 (5.4) 26.8 (4.5) 26.5 (5.6)d 27.3 (5.7) 26.1 (5.4)b 25.0 (5.7)b,c
Current smokers No. (%) 0e 194 (60)d 746 (36)a 350 (38) 321 (37) 75 (27)f
Pack-years 0.0 (0.1) 31.5 (21.5)d 48.7 (27.2)a 48.2 (28.4) 48.9 (25.7) 50.0 (27.6)
Lung function: FEV1 (L) 3.26 (0.78) 3.35 (0.76) 1.35 (0.52)
a 1.75 (0.45) 1.13 (0.27)b 0.72 (0.16)f
FEV1 (% predicted) 114.8 (13.8) 108.9 (12.0)
d 48.4 (15.7)a 63.1 (8.4) 40.3 (5.8)b 24.8 (3.7)f
FEV1/FVC (100) 81.0 (5.2) 79.3 (5.1) 44.6 (11.6)a 52.7 (8.8) 40.2 (8.8)b 31.7 (7.3)f
% reversibility 2.8 (4.5) 4.5 (5.6) 10.7 (13.6)a 11.1 (12.5) 11.1 (14.5) 8.2 (14.0)f
LAA% on CT 4.1 (4.2) 2.4 (3.1) 17.7 (12.2)a 12.2 (9.6) 20.1 (11.6)b 28.6 (12.4)f
Data expressed as mean (SD) unless otherwise specified; Lung function parameters are post-bronchodilator. NSCZ non-smoker controls;
CSZ control smokers; COPDZ chronic obstructive pulmonary disease; GOLDZ Global Initiative for Chronic Obstructive Lung Disease;
FEV1Z forced expired volume in 1 s; FVCZ forced vital capacity; BMIZ body mass index; LAA%Z percentage of low attenuation areas
(i.e. below 950 Hounsfields Units) on chest computed tomography; CT Z computed tomography.
a p < 0.001 compared with NSC and CS.
b p < 0.001 compared with GOLD 2 (p Z 0.029 for age).
c p < 0.04 compared with GOLD 3.
d p < 0.001 compared with NSC (p Z 0.003 for BMI).
e 11 (5%) of NSC were former smokers.
f p  0.002 compared with GOLD 2 and GOLD 3 (p Z 0.003 for percentage reversibility).
1072 C. Crim et al.controls and 582 COPD subjects). Spirometric indices in this
subset of subjects were similar to their respective cohort in
the entire population. Subjects with COPD demonstrated
evidence of air trapping (FRC 145.0  34.3% predicted) and
reduced specific conductance (SGaw) compared with both
control groups (online Table 1).IOS parameters
Non-smoking and smoking control subjects
Values (mean  SD) at baseline for R5, R20, R5  R20, X5, AX
and FRes from the 233 non-smoking control subjects with a<1
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-1.50
-1.00
-0.50
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
0 1 2
D
iff
er
en
ce
 b
et
w
ee
n 
Sc
re
en
in
g 
a
n
d 
3 
M
on
th
s
Mean of Scre
COPD Subjects Smoker co
Bias Lower Lim
Figure 1 BlandeAltman plots depicting the reproducibility betwe
(forced expiratory volume in 1 s) from non-smoking and smoking
subjects. The central horizontal line shows mean of differences anshown in Table 2. BlandeAltmanplotswere constructed from
the baseline and 3-month data for the respiratory system
resistance at 5Hz, R5 (Fig. 2) and also for R20, R5R20, AX and
X5 (online Fig. 1). Impedance parameters in this group were
fairly stable over this 3-month period. The coefficient of
repeatability for R5 for the non-smoking and smoking
controls combined was 0.13 kPa/L/s.
Of the smoking control subjects 95%, 93%, 94% and 95%
had values that fell within the normal range (i.e. 90%
confidence interval of the non-smoking controls) for R5, R20,
R5  R20, and AX, respectively. The smoking control
subjects with elevated values had a similar degree of CT-
assessed emphysema as the non-smoking controls. Thus,
the mean  SD LAA% in the 14/322 smoking control subjects
with an elevated R5 was 2.5  3.4% compared with3 4 5 6
ening and 3 Months
ntrols Non-smoker controls 
it Upper Limit
en the baseline values and measurements at 3 months for FEV1
control, and COPD (chronic obstructive pulmonary disease)
d the dashed lines represent the 95% limits of agreement.
Table 2 Baseline IOS (impulse oscillometry) impedance parameters in ECLIPSE subjects.
NSCa
(n Z 233)
CS
(n Z 322)
COPD
(n Z 2054)
GOLD 2
(n Z 915)
GOLD 3
(n Z 861)
GOLD 4
(n Z 278)
R5 (kPa/L/s) 0.33 (0.10) 0.31 (0.10) 0.49 (0.16)
b 0.45 (0.14) 0.51 (0.16)c 0.55 (0.19)d
R20 (kPa/L/s) 0.26 (0.07) 0.25 (0.07)
e 0.30 (0.08)b 0.29 (0.07) 0.31 (0.08)c 0.31 (0.09)f
R5  R20 (kPa/L/s) 0.07 (0.05) 0.06 (0.05) 0.19 (0.10)b 0.15 (0.09) 0.20 (0.10)c 0.24 (0.12)d
X5 (kPa/L/s) 0.10 (0.06) 0.09 (0.05) 0.29 (0.17)b 0.21 (0.13) 0.32 (0.16)c 0.44 (0.18)d
AX (Hz$kPa/L/s) 0.38 (0.40) 0.34 (0.35) 1.99 (1.46)b 1.37 (1.08) 2.25 (1.36)c 3.23 (1.79)d
FRes (Hz) 12.4 (3.4) 12.1 (3.2) 20.7 (5.2)
b 18.3 (4.3) 21.8 (4.7)c 25.3 (5.5)d
Data expressed as mean (SD) unless otherwise specified; Impedance parameters are post-bronchodilator. NSC Z non-smoker controls;
CSZ control smokers; COPDZ chronic obstructive pulmonary disease; GOLDZ Global Initiative for Chronic Obstructive Lung Disease;
R5; Z respiratory resistance (Rrs) at 5 Hz; R20;Z respiratory resistance (Rrs) at 20 Hz; R5  R20Z difference in respiratory resistance at
5 Hz and 20 Hz; X5 Z reactance at 5 Hz; AX Z integrated area of low-frequency reactance; FRes Z resonant frequency.
a 11 (5%) of NSC were former smokers.
b p < 0.001 compared with NSC and CS.
c p  0.001 compared with GOLD 2.
d p  0.001 compared with GOLD 2 and GOLD 3.
e p Z 0.041 compared with NSC.
f p Z 0.002 compared with GOLD 2. Comparisons between groups were adjusted for age and gender.
Impulse oscillometry in COPD subjects 10734.1  4.2% in the non-smoking control subjects. Conversely,
compared with the smoking control subjects who had
normal AX, those with an elevated AX (15 of 322) had
a significantly lower FEV1 (102.9  10.2% vs. 109.2  12.0%,
pZ 0.045), a difference that was not observed in the non-
smoking control subjects (114.9  13.5% vs. 112.8  18.2%,
p Z not significant). These smoking control subjects with
an elevated AX were somewhat older (60.7  8.9 years vs.
54.9  8.9 years, p Z 0.014), and a trend for a greater
smoking history (39.6  19.2 pack-years vs. 31.1  21.6
pack-years, p Z not significant), and 10 of these 15
subjects were current smokers compared with 184 (60%) of
those with a normal AX.
Subjects with COPD
As have been previously observed,8 the respiratory system
impedance components of resistance and reactance were
elevated in subjects with COPD; including low-frequency-0.75
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Figure 2 BlandeAltman plots depicting the reproducibility betw
respiratory system resistance at R5 (respiratory resistance (Rrs) at 5
(chronic obstructive pulmonary disease) subjects. The central ho
represent the 95% limits of agreement.reactance area (Table 2), with evidence of frequency
dependence of resistance, R5  R20 (Table 2 and Fig. 3).
BlandeAltman plots were constructed from the baseline and
3-month data for R5 (Fig. 2) and also for R20, R5 R20, AX and
X5 (online Fig. 1). As with spirometry, following inhaled
bronchodilators R5, R20, R5  R20, X5 and AX decreased in
subjects with COPD (of which the magnitude appeared to be
related to GOLD status), and other than AX, also improved in
controls (online Fig. 2). Interestingly, 61%, 86%, 40%, 34% and
29% of the COPD subjects with measurable baseline param-
eters of R5, R20, R5  R20, X5 and AX values respectively, had
values that fell within the normal range.
The subjects with COPD had a greater degree of CT
diagnosed emphysema (i.e. LAA%) than healthy non-
smokers (17.7  12.2% vs. 4.1  4.2%, p < 0.001). The
parameters of respiratory system impedance and CT index
of LAA% worsened as GOLD stages increased (Tables 1 and
2). Despite this apparent relationship, the actual correla-
tions between either LAA% with R5, R5  R20, or AX were0.75 1.00 1.25 1.50
ning and 3 Months
ntrols Non-smoker controls 
it Upper Limit
een the baseline values and measurements at 3 months for
Hz) from non-smoking and smoking control subjects and COPD
rizontal line shows mean of differences and the dashed lines
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Figure 3 Frequency dependence of respiratory system resistance. Respiratory system resistance as a function of frequency for
control and all COPD (chronic obstructive pulmonary disease) subjects, and by GOLD (Global Initiative for Chronic Obstructive Lung
Disease) severity stage. Error bars are 2 standard error of the mean.
1074 C. Crim et al.poor (Pearson’s r  0.16). However, within a GOLD stage
and compared with COPD subjects who had normal AX or
R5, COPD subjects with an abnormal AX tended to have
a lower FEV1, while subjects with an abnormal R5 surpris-
ingly tended to demonstrate less emphysema (i.e. lower
LAA%, Table 3). Finally, for the COPD subjects, there were
no significant correlations between any of the IOS param-
eters and pack years of smoking.
Other assessments
The spirometric parameter (the forced expiratory flow
between 25% and 75% of the vital capacity FEF25e75) has
previously been viewed as a crude surrogate to assess the
small airways. We therefore examined the correlation
between this parameter and R5  R20. The Pearson’s
correlation coefficient (r) for this relationship was 0.31
(p < 0.001) for the smoking control subjects and 0.34
(p < 0.001) for the COPD population (data not shown). Due
to skewed distributions of Raw and SGaw, we have calculated
Spearman correlation coefficients. The correlations
between Raw and AX and X5 are 0.65 and 0.68, respec-
tively (p < 0.001). The correlations between SGaw and AX
and X5 are 0.56 and 0.57, respectively (p < 0.001).Normative regression equations
We attempted to derive predictive regression equations for
the IOS parameters based on the data collected in the non-
smoking controls by linear and multiple regression. Each
model for an IOS parameter included age, height, weight,
gender, BMI and fat-free mass via bioimpedance. However,
for both the linear and multiple regression for all IOS
parameters, R2 values were <0.40.
Pasker and colleagues derived predictive reference
equations of a fourth degree polynomial for impedance
parameters between 6 and 24 Hz in 226 healthy subjects
using forced oscillation technique (FOT) generated withpseudo-random noise.19 We therefore used BlandeAltman
analysis to assess the degree of agreement between the
measured values of R20 in our non-smoking controls with
those predicted from Pasker’s equation. Although approxi-
mately 95% of values fell within the limits of agreement, it
appeared that at higher values of R20, the predicted values
tended to underestimate values directly obtained from IOS
measurements (data not shown).
Discussion
This study of the baseline and 3-month data on the value of
impulse oscillometry applied to the ECLIPSE cohort of COPD
subjects provided several important findings. First, that IOS
can be reliably obtained across centers in different conti-
nents. Second, several parameters of IOS differ between
subjects with COPD and smoking and non-smoking controls,
and help discriminate subjects with different degrees of
airflow limitation as classified by the ATS/ERS/GOLD stages.
Third, although some association exists between IOS
measurements and degree of CT measured emphysema,
they were modest and of limited clinical value.
Although COPD is a heterogeneous disease complex, only
the presence of airflow limitation as determined by
spirometry is required for the diagnosis in patients with an
appropriate medical history. Conversely, the varied mani-
festations of the disease are not, in and of themselves,
solely determined by the severity of the airflow limitation.
The ECLIPSE trial was designed to identify potential novel
endpoints that may subsequently provide a better charac-
terization of different subtypes/phenotypes of COPD
patients than currently accomplished with traditional
spirometry. Our data do not suggest that IOS or any
assessment of respiratory system impedance can be used as
a replacement for spirometry in the diagnosis of COPD.
Compared with the relative stability of FEV1 over short
periods (i.e. 3 months), respiratory impedance appears
slightly more variable over a similar time frame. This vari-
ability is not unique to our study and other investigators
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Impulse oscillometry in COPD subjects 1075have reported intra-individual variability either within-
day20,21 or day-to-day.20e22 Van den Elshout20 reported
a within-day and day-to-day coefficient of variation (CV) of
respiratory system resistance at 8 Hz (R8) of 8.3% and
10.1%, respectively (in comparison, the respective CV for
FEV1 was 6.0% and 6.4%). Gimeno et al
21 reported a within-
day and day-to-day CV of respiratory system resistance at
10 Hz (R10) of 8.56% and 10.79%, respectively; in contrast,
the respective CV for FEV1 was 2.35% and 2.21%. Similarly,
Neild and colleagues22 reported the day-to-day CV for R10
and FEV1 as 11.3% and 3.1%, respectively. Our data, in
conjunction with previous reports, suggest that although
more variable than FEV1, respiratory system impedance
remains fairly constant over 3 months.
Of perhaps greater importance is the appreciable
number of COPD subjects with normal impedance param-
eters. We observed that respiratory system resistance and
reactance, although impaired in the group as a whole, is
not altered in all patients with COPD nor is it related
specifically to the severity of the underlying airflow limi-
tation. In particular, these baseline data suggest that
regardless of the severity of airflow limitation, COPD
subjects with normal respiratory system impedance
(specifically AX and to a lesser extent resistance at 5 Hz)
may represent a distinct clinical subtype, in that they
appeared to have somewhat better spirometry.
These data also suggest that there may exist a sub-
population of ‘apparently healthy’ smoking individuals,
identified by having an elevated AX, who may have early
evidence of mild airflow limitation. One could speculate
that this group may represent individuals with ‘small
airways’ disease. However, the resolution of our CT images
does not allow us to look specifically at airways 2 mm in
internal diameter in order to relate these physiologic
observations with the anatomical correlate of interest.
Thus, these initial data need to be interpreted with
caution.
It has long been accepted that the early pathological
change in COPD patients is a respiratory bronchiolitis that
begins in the small airways.23e25 These early changes result
in an inhomogeneity of the mechanical properties of the
lung that can be assessed by modalities such as the
frequency-dependent nature of measured compliance,26
resistance27,28 or the multiple-breath nitrogen washout
test.29 It had been previously suggested that abnormalities
in indices from the ‘effort-independent’ portion of the
spirometric flow-volume loop (FEF25e75) may be indicative
of disease in the small airways in individuals with a normal
FEV1.
30 We found a weak association between FEF25e75 and
R5  R20 in the controls and COPD subjects. Although some
investigators have reported a relationship between struc-
tural changes in the small airways and FEF25e75,
31,32 the
correlations are fairly modest (w0.4), or non-existent.33
Actually, the variability of the measurement is large, with
an average CV of 25%.34 Thus, our inability to find a strong
correlation is not too surprising.
Our findings are also in agreement with earlier reports
that demonstrated minimal frequency dependence of
resistance in COPD subjects that is not evident in healthy
subjects.8 We expand upon these early reports and show
that the magnitude of this frequency dependency increases
with worsening airflow limitation as determined by GOLD
1076 C. Crim et al.status. However, it would not be totally correct to infer
that this index of lung heterogeneity is solely related to the
severity of airflow limitation as measured by spirometry.
For example, Dellaca` and colleagues have recently shown
that this frequency dependency is more evident in those
COPD subjects with demonstrable expiratory flow limitation
(EFL) compared with subjects without flow limitation.35
Moreover, only the subjects with EFL demonstrated an
improvement in Rrs (specifically, the inspiratory compo-
nent) and frequency dependency of resistance with inhaled
salbutamol.35 These authors also reported a greater
decrease in Rrs and R5  R19 in bronchodilator responders
compared with non-responders. Although in our study
impedance parameters were not partitioned between the
inspiratory and expiratory phases of respiration, we also
found that the decrease in IOS resistance following bron-
chodilators, as with the improvement in FEV1, appears
related to underlying severity of airflow limitation.
There are a limited number of studies that have
provided impedance parameters from a normal, non-
smoking population.19,36e38 Most of these studies that
derived normal values generated forced oscillations using
pseudo-random noise.19,36e37 The largest of these studies
was conducted by Pasker et al, whose group generated data
in 226 healthy, non-smoking subjects (126 males/106
females) at frequencies between 6 and 24 Hz.19 Applying
the regression equations provided in their paper to our non-
smoking control subjects generates reactance (SD) at 6 Hz
of 0.05  0.01 kPa/L/s, and resistance at 6 Hz and 20 Hz
of 0.28  0.03 and 0.29  0.02 kPa/L/s, respectively.
Conversely, Kohlha¨ufl and colleagues reported impedance
data on 55 (30 male/25 females) healthy non-smokers38
using a multifrequency IOS system as in the current study.
Values provided for X5, R5, R20 and FRes were approximately
0.10, 0.30, 0.25 kPa/L/s and 10.8 Hz, respectively. Thus,
other than a somewhat lower resonant frequency, the
resistance and reactance values previously reported with
both pseudo-random noise and IOS techniques are not too
dissimilar from those we observed. The age of our healthy
non-smokers were older than those in previous studies (e.g.
mean age 29e33 years in the report by Pasker and
colleagues19 and 37 years in the Kohlha¨ufl et al paper38)
with a mean age of 54 years in our cohort. Coe et al
reported a small increase in resonant frequency as well as
an increase in resistance at 6 Hz in some (but not all)
healthy, non-smokers over age 45 years compared with
younger non-smokers.37 However, Pasker reported that
although statistically significant, age had a quantitatively
weak effect on FOT reactance and resistance, and as such
was not included in their regression equations.19
In summary, we have shown that impulse oscillometry
can be used in large cohorts of subjects to assess respira-
tory system impedance. The reproducibility of such
measurements in this larger multi-center study extends
those previously reported in smaller, single center studies.
Similarly, at lower oscillation frequencies this modality
appears to be able to assess lung heterogeneity. As we
hypothesized, impulse oscillometry did not simply track
changes in spirometry but could be used to define different
subgroups of COPD patients. The longitudinal data obtained
with IOS from the ECLIPSE trial should provide additional
information as to the usefulness of this modality as anindependent and/or adjunctive predictive endpoint for
COPD morbidity.
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